<img src="https://secure.intelligence52.com/795232.png" style="display:none;">

An Introduction to Oncology Phase 1 Trial Design [Video]

By Marketing Quanticate
October 30, 2026

Oncology Phase 1 trial design now extends beyond identifying the maximum tolerated dose. This video explains how safety, pharmacokinetics, pharmacodynamics and early evidence of anti-tumour activity can inform dose selection, and why longer-term tolerability and trial delivery also need to be considered.

WHAT THIS VIDEO COVERS
• Why a dose that passes the initial safety assessment may still be difficult for patients to sustain
• How three-plus-three, model-assisted and model-based escalation designs use toxicity data
• How simulation can test dose-selection performance and account for delayed toxicity
• Why expansion cohorts and combination treatments require careful dose characterisation
• How biomarkers, data availability and site capability affect trial delivery
• The coordination demands of basket, umbrella and platform trials

A suitable dose and regimen must be supported by evidence that can be collected, reviewed and acted on within the trial. Understanding the connection between statistical design, clinical assessment and operational delivery can help teams identify potential problems before they affect dose decisions or patient recruitment.

Quanticate’s statistical consultancy team supports sponsors with dose-finding design, simulation, and operating characteristic evaluation to help ensure early-phase studies generate reliable, decision-ready evidence. If you’re planning an early oncology programme, request a consultation to discuss how our statisticians can support your Phase 1 trial design.

Request a Consultation